# NIH Reporter #1R37CA315256-01

Multi-directed prime-pull cancer immunotherapy using super-adjuvant nanoparticles

**Recipient:** University of Massachusetts Amherst

**Award Amount:** $416,468.00
**Ceiling:** $416,468.00

**Awarded:** June 29, 2026

**Identifier:** 1R37CA315256-01

The University of Massachusetts Amherst received NIH funding to study nanoparticle-based prime-pull vaccination using synergistic STING and TLR4 adjuvants, with the goal of strengthening anti-tumor immune responses in metastatic melanoma.

### Description

Funding for a project developing dual-adjuvant, dual-delivery nanoparticles to combine lymph-node priming and tumor-directed vaccination for cancer immunotherapy, using metastatic melanoma as a model.

[View original record](https://reporter.nih.gov/search/Z6-pLStXck6naeyMsC9RTw/project-details/11447033)
